Erasca, Inc. Stock Price, News & Analysis

Erasca (NASDAQ: ERAS) announced significant advancements in its RAS-targeting cancer therapy programs. The FDA cleared the IND for ERAS-0015, a pan-RAS molecular glue, and the company submitted an IND for ERAS-4001, a potential first-in-class pan-KRAS inhibitor. Both developments occurred ahead of schedule, with Phase 1 monotherapy data expected in 2026. The company also announced a strategic decision to seek partnership opportunities for naporafenib, extending their cash runway guidance from H2 2027 to H2 2028. ERAS-0015 targets approximately 2.7 million patients annually with RAS-mutant tumors, while ERAS-4001 addresses over 2.2 million patients with KRAS-mutant tumors. This strategic prioritization allows Erasca to focus on advancing its RAS-targeting franchise while maintaining over three years of projected cash runway.

Erasca (NASDAQ: ERAS), a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers, has announced its participation in the Bank of America Securities 2025 Health Care Conference. The event will take place at the Encore Hotel in Las Vegas, Nevada. The company's management will deliver a presentation on Wednesday, May 14, 2025, at 2:35 PM Pacific Time and will engage in one-on-one investor meetings. A live audio webcast will be accessible at Erasca.com/events, with a replay available for 30 days following the presentation.

Erasca presented new preclinical data at the 2025 AACR Annual Meeting, highlighting advances in their RAS-targeting cancer therapy franchise. The company showcased two key compounds:

ERAS-0015, a pan-RAS molecular glue, demonstrated:

• 8-21 times greater cyclophilin A binding versus competitor RMC-6236
• Strong anti-tumor activity at lower doses
• Effective tumor tissue distribution

ERAS-4001, a novel pan-KRAS inhibitor, showed:

• Selective targeting of both mutant and wildtype KRAS
• Strong tumor growth inhibition in multiple models
• Promising results when combined with anti-PD-1 or cetuximab

Additionally, the company identified first-in-class direct SHOC2 binders, representing a new approach to block cancer-causing RAS/MAPK pathway signaling. These developments reinforce Erasca's position in precision oncology for RAS/MAPK pathway-driven cancers.

Erasca (NASDAQ: ERAS) has announced three poster presentations at the upcoming 2025 AACR Annual Meeting in Chicago, scheduled for April 25-30, 2025. The presentations will showcase the company's advancements in precision oncology, specifically targeting RAS/MAPK pathway-driven cancers.

The presentations will feature:

• ERAS-0015: A potential best-in-class pan-RAS molecular glue, to be presented on April 27
• ERAS-4001: A pan-KRAS inhibitor showing robust anti-tumor activity, scheduled for April 29
• Novel direct SMP complex inhibitors, representing a potential first-in-class approach to block the RAS/MAPK pathway, to be presented on April 28

All posters will be available on Erasca's website following the presentations.

Erasca (NASDAQ: ERAS) reported its Q4 and full year 2024 financial results, highlighting significant progress in its RAS-targeting oncology programs. The company maintains a strong financial position with $440.5 million in cash and equivalents, expected to fund operations into H2 2027.

Key developments include the advancement of two promising candidates: ERAS-0015 (pan-RAS molecular glue) and ERAS-4001 (pan-KRAS inhibitor), both scheduled to enter clinical trials in 2025. The ongoing Phase 3 SEACRAFT-2 trial for naporafenib in NRASm melanoma is progressing well, with Stage 1 randomized data expected in H2 2025.

Financial results show R&D expenses of $26.1 million for Q4 2024 and $115.4 million for the full year. The company reported a net loss of $32.2 million for Q4 and $161.7 million for the full year 2024, or $(0.69) per share.

Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers, has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference. The event will take place at the Lotte New York Palace in New York.

The company's management will conduct a fireside chat on Thursday, February 6, 2025, at 9:30 am Eastern Time and will engage in one-on-one investor meetings. Interested parties can access a live audio webcast of the presentation through Erasca.com/events, where an archived replay will remain available for 30 days following the event.

Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The conference will be held at the Westin St. Francis Hotel in San Francisco, California.

The company's management will deliver a presentation on Tuesday, January 14, 2025, at 9:45 am Pacific Time and will engage in one-on-one meetings with investors. The presentation will be accessible via a live audio webcast on Erasca.com/events, with a replay available for 30 days following the event.

Erasca specializes in discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

Erasca (ERAS) reported Q3 2024 financial results and business updates, highlighting positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort. The company maintains a strong financial position with $463.3 million in cash and equivalents as of September 30, 2024, expected to fund operations into H1 2027. Q3 net loss was $31.2 million ($0.11 per share). R&D expenses increased to $27.6 million, while G&A expenses were $9.6 million. The company is advancing its RAS targeting franchise with planned IND submissions for ERAS-4001 in Q1 2025 and ERAS-0015 in H1 2025.

Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, announces its participation in three upcoming investor conferences. The company will present at the Guggenheim Securities Healthcare Innovation Conference in Boston (November 12), the Jefferies London Healthcare Conference (November 20), and the 7th Annual Evercore HealthCONx Conference in Coral Gables (December 4). Management will engage in one-on-one investor meetings, and live audio webcasts will be available on Erasca.com/events, with replays accessible for 90 days.